Indications for Cytostatic Therapy in Metastatic Breast Cancer

References

• Paterson A HG, Szafran O, Hanson J, et al. Responses to treatment and its influence on survival in metastatic breast cancer. Am J Clin Oncol 1985; 8: 283–92
   PubMed Web of Science ®Google Scholar
• Ahmann D, Schaid D J, Bisel H F, et al. The effect on survival of initiating chemotherapy in advanced breast cancer: poly-chemotherapy versus single drug. J Clin Oncol 1987; 5: 1928–32
   PubMedGoogle Scholar
• Petru E, Schmal D. No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy. J Cancer Res Clin Oncol 1988; 114: 183–5
   PubMed Web of Science ®Google Scholar
• McGuire W L. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987; 10: 5–9
   PubMed Web of Science ®Google Scholar
• Gundersen S, Kvinnsland S. Chemotherapy in advanced breast cancer. A review. Acta Oncol 1987; 26: 81–7
   PubMed Web of Science ®Google Scholar
• Davidson N E, Lippman M E. Treatment of metastatic breast cancer. Diagnosis and management of breast cancer, M E Lippman, A S Lichter, D N Danforth. Saunders, Philadelphia 1988; 375–406
   Google Scholar
• Garber J E, Henderson I C. The use of chemotherapy in metastatic breast cancer. Diagnosis and therapy of breast cancer, I C Henderson, 1989; 3: 807–21, Hematol Oncol Clin North Am
   Google Scholar
• Henderson I C, Hayes D F, Gelman R. Dose response in the treatment of breast cancer: a critical review. J Clin Oncol 1988; 6: 1501–15
   PubMed Web of Science ®Google Scholar
• Swenerton K D, Legha S S, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39: 1552–62
   PubMed Web of Science ®Google Scholar
• Henderson I C. Chemotherapy for advanced disease. Breast cancer: diagnosis and management, G Bonadonna. John Wiley &Sons, Chichester 1984; 247–80
   Google Scholar
• Coates A, Gebski V, Bishop J F, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Eng J Med 1987; 317: 1490–5
   PubMed Web of Science ®Google Scholar
• Tannock I F, Boyd N F, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–87
   PubMed Web of Science ®Google Scholar
• Brincker H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. Acta Oncol 1988; 27: 729–32
   PubMed Web of Science ®Google Scholar
• Skovlund E. Sequential two-sample methods in controlled clinical trials. dissertation, Universitas Osloensis, Oslo 1990
   Google Scholar
• Tubiana M, Pejovic M H, Koscielny S, Chavaudra N, Gioanni J, Malaise E P. Growth rate, kinetics of tumor cell proliferation and long term outcome in human breast cancer. Int J Cancer 1989; 44: 17–22
   PubMed Web of Science ®Google Scholar
• Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045–53
   PubMed Web of Science ®Google Scholar
• Dawson A E, Norton J A, Weinberg D S. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990; 136: 1115–24
   PubMed Web of Science ®Google Scholar
• Russo J, Russo I H. Immunocytochemical markers in breast cancer. Advances in immunohistochemistry, R A DeLellis. Raven Press, New York 1988; 431–75
   Google Scholar
• Søreide J A, Lea O A, Anda O, Skarstein A, Varhaug J E, Kvinnsland S. Progesterone-binding cyst protein (PBCP) in operable breast cancer. Correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Anticancer Res 1991; 11: 1323–6
   PubMedGoogle Scholar
• Thorpe S M, Rochefort H, Garcia M, et al. Association between high concentration of Mw 52000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008–14
   PubMed Web of Science ®Google Scholar
• Huff K K, Kaufman D, Gabbay K H, Spencer E M, Lippman M E, Dickson R B. Human breast cancer cells secrete an insulin-like growth factor-I-related polypeptide. Cancer Res 1986; 46: 4613–9
   PubMed Web of Science ®Google Scholar
• Clark G M, Sledge G W, Osborne C K, McGuire W L. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987; 5: 55–61
   PubMed Web of Science ®Google Scholar
• Harris A L. Epidermal growth factor receptor in human breast cancer. Recent Results Cancer Res 1989; 113: 70–7
   PubMedGoogle Scholar
• Perren T J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 1991; 63: 328–32
   PubMed Web of Science ®Google Scholar
• Borg Å, Sigurdsson H, Clark G M, et al. Association of INT2/HSTI co-amplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 1991; 63: 136–42
   PubMed Web of Science ®Google Scholar
• Merkel D E, Fuqua S AW, Tandon A K, Hill S M, Buzdar A U, McGuire W L. Electrophoretic analyis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 1989; 7: 1129–36
   PubMed Web of Science ®Google Scholar
• Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 1991; 27: 155–8
   PubMed Web of Science ®Google Scholar